 | • レポートコード：B-MOR-08469 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・製薬 |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、前臨床用イメージングの世界市場について調べ、前臨床用イメージングの世界規模、市場動向、市場環境、モダリティ別（光イメージングシステム、核イメージングシステム、マイクロMRI、マイクロ超音波、マイクロCT、光音響イメージングシステム、磁性微粒子イメージング（MPI）システム）分析、試薬別（前臨床イメージング用試薬、前臨床核イメージング用試薬、前臨床MRI造影剤、前臨床超音波造影剤、前臨床CT造影剤）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・前臨床用イメージングの世界市場インサイト ・前臨床用イメージングの世界市場環境 ・前臨床用イメージングの世界市場動向 ・前臨床用イメージングの世界市場規模 ・前臨床用イメージングの世界市場規模：モダリティ別（光イメージングシステム、核イメージングシステム、マイクロMRI、マイクロ超音波、マイクロCT、光音響イメージングシステム、磁性微粒子イメージング（MPI）システム） ・前臨床用イメージングの世界市場規模：試薬別（前臨床イメージング用試薬、前臨床核イメージング用試薬、前臨床MRI造影剤、前臨床超音波造影剤、前臨床CT造影剤） ・前臨床用イメージングの世界市場：地域別市場規模・分析 ・前臨床用イメージングの北米市場規模・予測 ・前臨床用イメージングのアメリカ市場規模・予測 ・前臨床用イメージングのヨーロッパ市場規模・予測 ・前臨床用イメージングのアジア市場規模・予測 ・前臨床用イメージングの日本市場規模・予測 ・前臨床用イメージングの中国市場規模・予測 ・前臨床用イメージングのインド市場規模・予測 ・前臨床用イメージングの韓国市場規模・予測 ・関連企業情報・競争状況 |
The global preclinical imaging market is projected to register a CAGR of approximately 6% during 2018-2023 (the forecast period).
Technological Advancements in Molecular Imaging
Advanced and hybrid imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and single photon emission computed tomography (SPECT), are invaluable in providing better care to patients. Owing to technological advances, imaging modalities provide value-based care to patients. These advances enable clinicians to access and collate integrated patient data, provide improved workflow and automation, and also contribute to the development of personalized medicines. Therefore, advancements in molecular imaging modalities are driving the growth of the global preclinical imaging market. Moreover, factors, like growing demand for non-invasive small animal imaging techniques and increase in preclinical research funding by, both, private and government entities are a few factors that are driving the market growth.
Strict Regulations in Preclinical Research
There are three different reasons behind the minimal development of new drugs and the reduced number of new chemical entities that are launched every year. Firstly, both the preclinical and clinical evaluations of a new drug have become more time-consuming than ever, especially the most in-demand extensive and long-term toxicological studies. Besides, careful and more sophisticated experimental analysis of a new drug as well as clinical trial, carried out to demonstrate their efficacy, require not only a long period of investigation but also a heavy financial investment. Secondly, drug research within the pharmaceutical industry is in a critical phase, since it lacks innovation and in many companies beats traditional tracks. Thirdly, the increasing requests, orders, and regulations, issued by governments or governmental agencies, who are responsible for a proper drug administration, have put up barriers and hurdles that can only be overcome by the efforts which are quite disproportional to the expected result or may be so discouraging that they prevent the manufacturers from pursuing certain lines of research. Consequently, the strict regulations imposed on preclinical research is hindering the market growth. Additionally, factors, like high costs associated with the installation and operation of preclinical imaging modalities, are hindering the market growth.
Bioluminescence and Fluorescence Imaging Systems are among the Most Widely Employed Modalities in Preclinical Imaging
Non-invasive imaging of molecular events and interactions in living small animal models have gained importance in the preclinical research. Tracer methods, which rely on the introduction of a radioactive substance in very small concentrations, are widely used in preclinical research and drug discovery. Consequently, bioluminescence and fluorescence imaging systems are the most widely used imaging modalities in the market and, therefore, this segment holds the largest market share, in terms of revenue.
Key Developments in the Market
• March 2017 – Li-Cor Biosciences sponsored its first clinical trial for an infrared imaging agent to be used in hysterectomy patients.
• September 2017 – Aspect Imaging, a world leader in design and development of compact magnetic resonance systems for preclinical, medical and industrial applications, announced that Quantum analytics would be its exclusive US Distributor for Aspect Imaging’s Industrial product portfolio.
Major Players – ASPECT IMAGING LTD, BRUKER CORPORATION, FUJIFILM HOLDINGS CORPORATION, LI-COR BIOSCIENCES, MEDISO LTD, MILABS BV, MILTENYI BIOTEC GMBH, MR SOLUTIONS LTD, PERKINELMER INC. AND TRIFOIL IMAGING, among others.
Reasons to Purchase this Report
• Current and future global preclinical imaging market outlook in the developed and emerging markets
• Various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest rates growth during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product And Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Technological Advancements in Molecular Imaging
6.1.2 Increasing Demand for Non-invasive Small Animal Imaging Techniques
6.1.3 Increase in Preclinical Research Funding, by Both Private and Public Organizations
6.2 Market Restraints
6.2.1 Strict Regualtions in Preclincal Research
6.2.2 High Installation and Operational Costs associated with Preclinical Imaging Modalities
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Modality
7.1.1 Optical Imaging Systems
7.1.1.1 Bioluminescence/Fluorescence Imaging Systems
7.1.1.2 Standalone Fluorescence Imaging Systems
7.1.1.3 Optical + X ray/ Optical + CT systems
7.1.2 Nuclear Imaging Systems
7.1.2.1 Micro-PET Systems
7.1.2.2 Micro-SPECT Systems
7.1.2.3 Trimodality Systems
7.1.3 Micro-MRI
7.1.4 Micro-Ultrasound
7.1.5 Micro-CT
7.1.6 Photoacoustic Imaging Systems
7.1.7 Magnetic Particle Imaging (MPI) Systems
7.2 By Reagent
7.2.1 Preclinical Optical Imaging Reagents
7.2.2 Preclinical Nuclear Imaging Reagents
7.2.3 Preclinical MRI Contrast Agents
7.2.4 Preclinical Ultrasound Contrast Agents
7.2.5 Preclinical CT Contrast Agents
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 United Kingdom
7.3.2.2 Germany
7.3.2.3 France
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Aspect Imaging Ltd
9.2 Bruker Corporation
9.3 Fujifilm Holdings Corporation
9.4 Li-Cor Biosciences
9.5 Mediso Ltd
9.6 Milabs BV
9.7 Miltenyi Biotec GmbH
9.8 MR Solutions Ltd
9.9 PerkinElmer Inc.
9.10 Trifoil Imaging
9.11 List Not Exhaustive
10. Future of the Market